semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Epilepsy Children, Only Quality of Life Seizures Patient Compliance • Child aged 5 to 17 Child who has received complete information on the organization of the research and who has not objected to his participation and the exploitation of his data Holder (s) of the parental authority present (s) having received the complete information on the organization of the research and not being opposed to the participation and the exploitation of the data of his child Epileptic child Follow-up at the neuro pediatric department of CHRU Nancy  epileptic encephalopathy Multiply handicapped child
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Hemorrhoids Male & female patients 18 to 65 years old Patients with acute hemorrhoids 1 and 2 stage (with thrombosis (external, internal, mixed), including cases with bleeding) Prescription of fluocortolone + lidocaine as a part of routine clinical practice  Patients participating in an investigational program with interventions outside of routine clinical practice Hemorrhoid with stage ˃ II Contraindications for use of Relief PRO in the approved product label Anemia and/or severe/profuse hemorrhoid bleeding Surgery in perianal region in anamnesis Concomitant treatment with antibiotics/antiseptics, antithrombotics, antineoplastic and/or immunosuppressant Inflammatory bowel disease Hepatic diseases in severe and acute stages Colorectal cancer Purulent-inflammatory diseases of the perianal region and anal canal
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.0,  Pulpotomy Children Children aged 5-8 years with at least two bilateral deep carious primary molars indicated for pulpotomy Children who are physically and mentally healthy without any known medical history of systemic conditions contraindicating pulp therapy Children who had "positive" or "definitely positive" behavioral ratings according to the Frankl behavior classification scale (Frankl, 1962) Children whose parents signed an informed consent for the child's participation in the study. Teeth Teeth were selected according to clinical and radiographic criteria. Clinically, the study included Teeth with restorable crowns Teeth with pathologic carious exposure of vital pulps Teeth with no tenderness to percussion, physiologic or pathologic mobility or any clinical evidence of pulp inflammation or degeneration such as history of swelling, pain or presence of sinus tract. Radiographically, the recruited teeth should have Normal radiographic appearance with healthy supporting tissues No pulp calcification  Any child complained of clinical signs such as pain, swelling, abnormal mobility, vertical or lateral tenderness to percussion was excluded from the study Radiographically, any child with signs of internal or external root resorption or periapical or inter-radicular pathology was omitted from the study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 8.0-11.0,  Schistosomiasis School children, of public schools in villages of Saint Louis region (Senegal), female or male, 8 to 11 years old (inclusive) at the time of inclusion Residence in the area during the period of the study Free of obvious/severe health problems except schistosomiasis, as established by clinical examination Written informed consent to participate obtained from subject's parents or legal guardian Free of obvious/severe health problems except schistosomiasis, established by blood analysis, i.e. hematological exams, liver and renal function tests Treated with 40mg/kg Praziquantel (PZQ) before (W-2 to W-4 before the first injection) in case of infection with S. mansoni and S. haematobium Children of Group 1: not infected, no schistosomiasis history and living in area/village free of Sm and Sh transmission Children Groups 2 & 3: infected with mansoni or/and haematobium schistosomiasis  School child who does not respond to one of the Child under 20kg of body weight Vaccination within 90 days preceding the first dose of Sm14 vaccine candidate, or planned use during the study period Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immuno-modifying drugs Known hypersensitivity to any component in the Sm14 vaccine or history of allergic disease Knowledge of non-infectious chronic disease Known acute disease Other conditions which in opinion of the PI may potentially represent a danger for the patient to be enrolled
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis, Postmenopausal Women at least 50 years of age who are postmenopausal. Postmenopausal is defined as being amenorrheic for at a period of at least 12 months. 2. Diagnosis of osteoporosis by T score of < -2.5 at either lumbar spine or the hip/femoral neck, or osteopenia that qualifies for treatment by FRAX calculation (10-year risk of hip fracture > 3% and/or major osteoporotic fracture of > 20%). 3a. Subjects who have had chronic treatment of denosumab (as defined as > 1 year [at least 3 6-monthly injections]) or zoledronic acid (defined as ≥ 2 years [at least 2 annual injections]) . Note: At the time of treatment initiation, subjects must have met for on-label use (e.g. criterion 2 above). OR 3b. Subjects who are naïve to treatment with denosumab and/or zoledronic acid  Renal insufficiency, with glomerular filtration rate (GFR) < 35 ml/min. 2. Hypocalcemia within 6 months of study initiation. 3. Known hypersensitivity to denosumab or zoledronic acid. 4. Medications that could alter bone turnover including prednisone, anti-rheumatic medications, anti-metabolites (Cytoxan). Subjects who have been on stable doses of thyroid replacement or diabetes medications for more than 3 months are eligible. 5. Evidence of untreated oral cavities or oral infections. Preventative dental exams should be performed before starting denosumab or zoledronic acid. Subjects must avoid invasive dental procedures during treatment with denosumab or zoledronic acid
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Muscle Tone Increased Age ≥ 21 years Voluntarily signed informed consent form BMI ≤ 30 kg/m2 Women of child-bearing potential are required to use birth control measures during the whole duration of the study Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring during study participation Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation  Cardiac pacemakers Implanted defibrillators, implanted neurostimulators Electronic implants Pulmonary insufficiency Metal implants Drug pumps Malignant tumor Fever Pregnancy Breastfeeding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Joint Disease Joint Instability Osteoarthritis Bone Malalignment Men or women aged 20 to 65 years Patients who have had orthopaedic surgery Presence in the file of a preoperative CT scan and/or magnetic resonance imaging (MRI) Presence in the file of a CT scan and/or MRI postoperatively at a distance from the operation (at least 4 weeks) Presence in the file of an operating report describing the procedure in detail with access routes, operating times, type of equipment and possible complications Patient who has authorized the anonymous use of data from his pre and post surgical examinations Patient who is a member of a social security organisation for non-inclusion Patient who has expressed his refusal to use his medical data Minor, patient under guardianship, inability to receive information and express consent Pregnant women
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fibrous Dysplasia of Bone Control population  men and women years-old and over consulting a rheumatologist or an orthopedist for arthrosis have scheduled surgery for hip or knee replacement surgery or any intervention involving the lower limb or upper limb. Patients with Fibrous dysplasia men and women years-old and over with a diagnosis of fibrous dysplasia previously established by a rheumatologist  Refusal to participate in the study Long term corticosteroids treatment (> 3 months) Treated osteoporosis Chronic inflammatory rheumatism (rheumatoid arthritis, psoriasic arthritis, spondyloarthropathy) Collagen disease (osteogenesis imperfecta…) Paget's disease, benign bone tumors Uncontrolled hypo/hyper-thyroidism, hypo/hyper-parathryoidism Severe renal impairment (GFR < 30 ml/min/1.73m2) Cancer or bone metastases (current or in the past two years)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypertension,Essential o men and women (females of childbearing potential must be using highly effective contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner) Females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test between 40 and 80 years of age documented history of hypertension smokers/non smokers R type 2 diabetes R Moderate to severe kidney disease (GFR >30 and <60 ml/min/1.73m2 (estimated MDRD) R Hypercholesterolemia R Receiving an optimal standard antihypertensive treatment for at least 6 months, stable for at least 15 days All other concomitant treatments stabilized at least for the preceding 15 days  o Females of childbearing potential not using highly effective contraceptive precautions Patients with obstructive (>50% diameter reduction) CAD on the LAD (based on invasive angiography or coronary CTA) or with evidence of previous myocardial infarction or history of revascularization in the LAD territory CAD on the RCA or CX with diameter reduction > 50% (based on invasive angiography or coronary CTA) , either native or revascularized (stent) Patients with infectious disease and/or chronic inflammatory diseases Epicardial coronary arteries spasm Patients with severe valve disease and/or significant left ventricular wall motion abnormalities Patients under treatment with non-selective beta blockers including propranolol, nadolol, pindolol, labetalol, penbutolol, sotalol, carvedilol, and timolol Contraindications to dipyridamole infusion: asthma, bronchospasm, previous < 24 hours ingestion of phylline derivatives (tea, coffee, cola, xanthines and chocolate) sick sinus syndrome, advanced AV block (second and third degree), systolic blood pressure < 90 mmHg, cerebral ischemia, severe sinus bradycardia (heart rate <40/min), use of dipyridamole during the last 24 h, severe atherosclerotic lesions of extracranial artery >75% Acute treatment or treatment for acute diseases Patients receiving steroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-70.0,  Infection Patient age from 16 to 70 yrs old Patient needs surgical teeth extraction (subject tooth will be removed using osteotomy by motorised drill)  Patients refusing the preoperative dose of oral co-amoxiclav, and unwilling to take part  Patients who are allergic to co-amoxiclve, amoxicillin or metronidazole Patient are on warfarin medication
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Paget Disease Subject that participated in ZiPP Participant willing and able to consent and comply with the study protocol  Unable or unwilling to provide informed consent
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 9.0-11.0,  Bone Health Screened to be generally healthy as determined by standard medical assessment on physical and mental health Tanner stage 2 based on breast development for girls, and pubic hair in boys. Girls will have to be premenarcheal Having obtained his/her informed consent and parents or legal guardians consent  History of serious medical conditions such as intestinal or severe metabolic diseases, disorders such as diabetes, renal, hepatic or pancreatic diseases, disorders, ulcer, hyperthyroidism, malignance, chronic malnutrition, anaemia History or on therapy with medication known to interfere with bone metabolism such as steroids, hormones, diuretics, cortisone or anti-seizure medication Taking regularly any nutritional supplements and unwilling to stop for the study